Your Global Leader in Stem Cell Market Research
Stemmatters is a Portuguese contract development and manufacturing (CDMO) organisation based in Barco, Guimarães. Originally a spin-off from University of Minho, it offers contract development and manufacturing services for cell-based advanced therapies, exosomes, blood-derived biologics, tissue products, biomaterials, and combination devices.
In the interview below, we explore Stemmatters history, services, manufacturing facilities, and future goals. Enjoy! [Read more…]
Umbilical cord stem cells are present within the cord that connects a newborn to its mother and uses of these birth cells include treating cancers, diseases, injuries, and more. Umbilical cord blood contains hematopoietic stem cells (HSCs), which are multipotent stem cells that can give rise to other blood and immune system cells.
Stem cells can also be collected from a newborn’s:
Most commonly, hematopoietic stem cells (HSCs) from cord blood are used to treat blood cancers, such as leukemia. When compared to hematopoietic stem cells from genetically matched bone marrow donor, cord blood HSCs may provide some medical advantages, including fewer immune system complications, such as graft-versus-host disease (GvHD).
In recent years, regenerative medicine has continued to increase the list of medical uses for stem cells from umbilical cord. Find out more about current and future uses of umbilical cord stem cells below.
In this article:
As of today, the list of publicly announced RMAT’s has risen to 37. However, the U.S. FDA states it has received 115 total requests for RMAT designations and granted 44.
This means that slightly over one-third of RMAT applications get approved.
CARsgen Therapeutics’ chimeric antigen receptor T-cell therapy (CT053) for patients with relapsed or refractory multiple myeloma was the most recent addition on October 28, 2019.
SHANGHAI, Oct. 28, 2019 — CARsgen Therapeutics Co. Ltd., a clinical-stage biopharmaceutical company today announced that the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational CT053 CAR-T cell therapy. CT053 is a fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cell therapy for the treatment of relapsed and/or refractory multiple myeloma (rrMM). [Read more…]
How much is stem cell therapy? As stated by CBC Canada, the cost of stem cell therapy is $5,000 to $8,000 per stem cell treatment for patients. According to a Twitter poll by BioInformant, the cost can be even higher, with stem cell treatments costing as much as $25,000 or more. This article explores the key factors that impact the cost of stem cell therapy, including the type of stem cells used within the protocol, the number of treatments required, and the site of the clinic. It also provides pricing quotes from stem cell clinics within the U.S. and worldwide.
In this article:
